Nasus Pharma Ltd (NSRX)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Nasus Pharma Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 11.71M shares outstanding
ILNasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Leadership
Ehud Moshe Gilboa
Co-Founder & Executive Chairman
Dalia Megiddo
Co-Founder, Director, Chief Medical Officer & Chief Development Officer?
Dan Teleman
Chief Executive Officer & Director
Eyal Rubin
CFO & Executive VP
Employees
7
Country
IL
Sector
Healthcare
Website
nasuspharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Teleman Dan Benjamin | Chief Executive Officer | Purchase | 6.5K | $20.3K | Jun 17, 2026 |
| Teleman Dan Benjamin | Chief Executive Officer | Purchase | 2.9K | $10.9K | Apr 22, 2026 |
| Teleman Dan Benjamin | Chief Executive Officer | Purchase | 15.0K | $30.6K | Mar 31, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Udi Gilboa · may incl. warrants· filed Nov 2025 | 1.9M | 16.2% | 13G |
Dr. Dalia Megiddo · may incl. warrants· filed Nov 2025 | 1.9M | 16.1% | 13G |
Dr. Ronnie Hershman · may incl. warrants· filed Nov 2025 | 1.4M | 11.8% | 13G |
BALYASNY ASSET MANAGEMENT L.P. | 898.5K | 7.7% | 13F |
Cable Car Capital, LP | 616.1K | 5.3% | 13F |
Capital Point Ltd. · may incl. warrants· filed Aug 2025 | 575.1K | 4.9% | 13G |
Velan Capital Investment Management LP | 359.4K | 3.1% | 13F |
 Teleman Dan Benjamin Chief Executive Officer, Director | 163.5K | 1.4% | FORM 4 |
Hudson Bay Capital Management LP | 134.8K | 1.2% | 13F |
Bleichroeder LP | 89.8K | 0.8% | 13F |
Insiders
- Teleman Dan BenjaminChief Executive Officer
based on 11.71M shares outstanding
IL30d Avg
27.68K
60d Avg
19.41K
90d Avg
18.05K